Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression
Background: Treatment of major depression is crucial to decrease the burden of disease. Hence, in this study, the efficacy of Botox was compared with placebo for treatment of patients with major depression.
Methods: In this randomized clinical trial, 28 consecutive patients with major depression were enrolled. The patients were randomly assigned to receive either Botox or placebo and the scores of Beck Depression Inventory were determined and compared at baseline and after two and six weeks in the groups and between the groups. In addition, the drug adverse effects were compared between groups. This study had been registered in TCTR with TCTR20170409001 code.
Results: There was a statistically significant difference two group for 6th week Beck Score (P=0.004), but at baseline and after two weeks, there was no significant difference (P>0.05). None of the patients experienced side effects.
Conclusion: Finally, Botox is effective for treatment of patients with major depression and it has a high safety.
Rueda-Jaimes GE, Camacho López PA, Navarro-Mancilla AA (2008). Prevalence of Obsessive Compulsive Disorder and its comorbidity with Major Depressive Disorder in adolescent students. Vertex, 19(78):5-9.
Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER (1993). The economic burden of depression in 1990. J Clin Psychiatry, 54(11):405-18.
Wang H, Qi H, Wang BS, Cui YY, Zhu L, Rong ZX, Chen HZ (2008). Is acupuncture beneficial in depression: a meta-analysis of 8 randomized controlled trials? J Affect Disord, 111(2-3):125-34.
Heckmann M, Ceballos-Baumann A (2007). Botulinum toxin overrides depression: not surprising, yet sensational. Dermatol Surg, 33(6):765.
Finzi E (2013). Antidepressant effects of botuli-num toxin A: scientific rationale. J Psychiatry Neurosci, 38(5): E29.
Fagien S, Brandt FS (2001). Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella. Clin Plast Surg, 28(1):127-48.
Dastoor SF, Misch CE, Wang HL (2007). Botulinum toxin (Botox) to enhance facial macroesthetics: a literature review. J Oral Implantol, 33(3):164-71.
Fagien S (1999). Botox for the treatment of dy-namic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg, 103(2):701-13.
Brandt FS, Bellman B (1998). Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg, 24(11):1232-4.
Ascher B, Rossi B (2004). Botulinum toxin and wrinkles: few side effects and effective combining procedures with other treatments. Ann Chir Plast Esthet, 49(5):537-52.
Hawlik AE, Freudenmann RW, Pinkhardt EH, Schönfeldt-Lecuona CJ, Gahr M (2014). Botuli-num toxin for the treatment of major depres-sive disorder. Fortschr Neurol Psychiatr, 82(2):93-9.
Han C, Park GY, Wang SM, Lee SY, Lee SJ, Bahk WM, et al (2012). Can botulinum toxin improve mood in depressed patients? Expert Rev Neurother, 12(9):1049-51.
Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, et al (2012). Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res, 46(5):574-81.
Davis JI, Senghas A, Brandt F, Ochsner KN (2010). The effects of BOTOX injections on emotional experience. Emotion, 10(3):433-40.
Ochudlo S, Bryniarski P, Opala G (2007). Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm. Parkinsonism Relat Disord, 13(8):505-8.
Finzi E, Wasserman E (2006). Treatment of depression with botulinum toxin A: a case series. Dermatol Surg, 32(5):645-9.
|Issue||Vol 46 No 7 (2017)|
|Botox Treatment Major depression|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|